Lineage Cell Therapeutics financials
$0.9475−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M | $1.8M | $3.5M |
| Gross profit | $14.6M | $9.5M | $8.3M | $14.0M | $2.9M | $1.4M | $3.1M |
| Gross margin | 100.0% | 100.0% | 92.5% | 95.0% | 67.2% | 78.9% | 88.3% |
| Operating income | -$36.6M | -$21.5M | -$24.7M | -$22.5M | -$49.2M | -$26.4M | -$38.9M |
| Net income | -$63.5M | -$18.6M | -$21.5M | -$26.3M | -$43.0M | -$20.6M | -$11.7M |
| Net margin | −436.5% | −195.9% | −240.2% | −178.7% | −991.0% | −1130.8% | −333.1% |
| Diluted EPS | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 |
| EBITDA | -$21.1M | -$20.9M | -$24.0M | -$21.8M | -$48.3M | -$24.5M | -$35.7M |
| Operating cash flow | -$18.9M | -$23.1M | -$28.6M | $1.1M | -$23.6M | -$19.8M | -$31.9M |
| Free cash flow | -$19.4M | -$23.7M | -$29.2M | $646.0K | -$23.9M | -$19.8M | -$32.4M |
| Diluted shares | 230.1M | 200.2M | 172.7M | 169.8M | 164.5M | 150.0M | 145.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.8M | $45.8M | $35.4M | $11.4M | $55.7M | $32.6M |
| Short-term investments | $15.0M | $2.0M | $50.0K | $46.5M | $2.6M | $9.0M |
| Total debt | $69.0K | $122.0K | $143.0K | $120.0K | $60.0K | $42.0K |
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M | $107.9M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M | $12.8M |
| Shareholders' equity | $43.3M | $77.0M | $62.0M | $71.9M | $90.9M | $95.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology